Patient Identification tools in China

Part
01
of ten
Part
01

Emerging Technology Companies - Patient Identification Tools: China

The companies developing platforms (apps, websites, and others) or technologies which are providing patient identification tools either based in China or serving the Chinese market are AmoyDx, Congenica, and Tencent Holdings. On the attached spreadsheet on the tab "Emerging Tech Companies", in rows 2-4 the available information can be found. Below is a summary of the findings.

KEY FINDINGS


RESEARCH STRATEGY

To provide an answer, we had to broaden the search criteria beyond patient identification of COPD Chronic Obstructive Pulmonary Disease (COPD). We were also unable to find companies building research tools through direct research. Instead, we had to find news articles about partnerships in patient identification between companies that were catering to the Chinese market. Our specific research path was as follows.

First, we tried to find the websites of companies that are developing these platforms and tools. The search, however, gave us sources that were not relevant or helpful. We discovered that 'patient identification' is mostly used within the context of biometric and wearable devices in the healthcare sector. We also tried to determine if international companies (like RightPatient) which provide patient identification tools had ventured into China, but this was a dead end. Next, we looked for news articles about patient identification technology in China and this provided us with information about a partnership that AmoyDx had formed. So we looked for more news articles about partnerships around patient identification and we found news about Congenica and Tencent Holdings. Last, we tried to find research publications about patient identification to see if this could lead us to companies (either based in China or serving the Chinese market) developing platforms or technologies providing patient identification tools. This, however, only gave us results about privacy and safety concerns in the Chinese healthcare, and other sources that were not relevant or helpful.

After exhausting all our research strategies, we concluded that there are only three companies involved in developing platforms or technologies which are providing patient identification tools either based in China or serving the Chinese market.
Part
02
of ten
Part
02

Concept of Patient Identification Tools

While there was no preexisting information to provide a high-level overview of how companies are integrating patient identification tools in the China market, we have used the available data to compile some helpful findings that are relevant to the research. Our research revealed that there is a lack of a unique patient identifier that works across multiple hospital information systems such as HIS, LIS, PACS, and others.

Helpful Findings

Patient Identification Tools

  • Patient Identification Tools in China serve to link all patient data across multiple systems together to provide a coherent service. Unfortunately, there is a lack of a unique patient identifier that works across multiple hospital information systems such as HIS, LIS, PACS, and others. This implies that healthcare providers mostly rely on patients' demographic data to identify their medical records in the electronic health record systems.
  • Electronic health record (EHR) system in China vary significantly by the hospital and are usually not integrated; thus patients often must bring with them a printed health record if they want to see doctors in different hospitals.
  • The current Chinese medical system cannot track a patient through electronic record systems for clinical purposes as there is no unified national platform that can consolidate all the data from all healthcare institutions in China.
  • The main barrier to conducting a “deep patient” study, where machine learning is used to predict future adverse events using medical data, is obtaining the longitudinal data and outcomes of each patient from electronic records.
  • Furthermore, the vast differences in medical practice raise concerns about the accuracy of data.
  • The lack of an established referral system and the heterogeneity in the quality of healthcare contribute to “medical migration,” when patients travel to different provinces and cities to seek medical care.

Digital Health in China

  • In November 2017, the Chinese government, together with four partnering companies, including Tencent, established the AI Medical Innovation System or AIMIS.
  • AIMIS is an AI powered diagnostic medical imaging service that works by using images of patient tissue that are fed into the AI software to determine the within four seconds the status of the bode (i.e., if it is normal, inflamed, or cancerous).
  • AIMIS currently offers 90 percent accuracy for diagnosis of esophageal cancer, 95 percent for lung sarcoidosis, and 97 percent for diabetic retinopathy.
  • The technological aids are massive help to overworked doctors in providing patients with correct diagnoses.
  • Another digital health in China is the robot named Xiaoyi (meaning little doctor) that can learn, reason, and make judgments by itself.
  • The creators think that it could capture and analyze patient information and help make an initial diagnosis. Thus, it doesn’t aim to replace doctors, but only to lift the burden off the shoulders of physicians.

Research Strategy

We first looked for preexisting information on the concept of patient identification, how companies are integrating Patient identification tools in the China market, and patient identification tools specific to COPD (Chronic Obstructive Pulmonary Disease). We searched through China’s government website, local and national media reports, industry reports or paywall market reports and medical reports, journals, scholarly articles. But unfortunately, we found no information on patient identification tools from government sources, industry reports, and market reports. Most information we found was the current status and overview of COPD, China patient care monitoring equipment, the country's healthcare system, and the overview identifier tools in the China market which are not related with the treatment.
Next, we then attempted to triangulate the request by searching for key players or top companies implementing this technology in China. We searched through credible sites like English.CCTV, Reuters, CNBC, and Xinhuanet, but found no news or companies implementing this technology in the country. Instead, what we found was International Health Care System Profiles and China's current healthcare system, among others.

After we were unable to find information on patient identification tools from the top or key players in the industry, we then attempted to triangulate for any patents filed by any companies of any sizes in China relating to patient ID. We searched sources such as Google Patents, Patentscope, and China National Intellectual Property Administration. We were hoping to find companies of any size in the patient identification tools for us to provide a high-level overview of how companies are integrating patient identification tools in the China market. But unfortunately, there was no information on patents filed by any company relating to our research.
Since there is no publicly available information to provide a high-level overview of how patient identification tools being integrated in China market, we have presented some helpful findings which we found during our research in the section above.
Part
03
of ten
Part
03

Patient ID - Competitive Landscape 1

After searching extensively through their websites, annual reports, press releases, as well as relevant media sites and patent databases, it has been concluded that GSK and Pfizer don't have any involvement with patient identification tools in China. As such, columns B and C of the attached spreadsheet have been filled with NA. Below are helpful findings, as well as details of the research strategies.

PATIENT ID TOOLS IN CHINA — GLAXO SMITHKLINE AND PFIZER

  • Pfizer has several partnerships, but none has to do with patient identification tools in China.
  • Pfizer's annual report details its investments, activities, and expenditures, but has no mention of patient identification tools in China.
  • GSK China has an 'in China, with China, for China' strategy that has led to several collaborations, innovations, and initiatives, but none is in the area of patient identification tools.
  • GSK China's research didn't detail any patient identification tools, and its main products/pipeline didn't either.
  • GSK's annual report describes its investments, partnerships, activities in China and expenditures, but has no mention of patient identification tools in China.

RESEARCH STRATEGY

There aren't any usage, investment, initiatives, or ownership of technologies involving patient identification tools in China for GSK and Pfizer. We started by searching through their websites, annual reports, and press releases, looking at their partnerships and expenditures. However, we didn't find any Chinese alliances in the area of patient identification tool. Pfizer's partnership page was on its website, and that of GSK was on its GSK China website and annual report. The GSK China website revealed a partnership with Ali Health in the area of vaccines. We also looked at their products, including those in the pipeline, but didn't find any patient identification tools for China.

Next, we searched for mentions of the activities of GSK and Pfizer on reputable media sites such as PR Newswire, Pharma Week, FiercePharma, PharmaTimes, and South China Morning Post. Again, we didn't find any involvement with patient identification tools in China for both companies. For GSK, we found partnerships with JD.com (to bring integrated medical services to its Chinese customers) and Ali Health (to aid access to cervical cancer vaccine). For Pfizer, we found a partnership with Jianke.com in the area of retail to improve its brand awareness.

Finally, we searched for patents filed by GSK and Pfizer in China from sources such as Wipo and Google Patents to see if they had filed any patents relating to patient ID. We still didn't find any.
Part
04
of ten
Part
04

Patient ID - Competitive Landscape 2

Merck and Amgen have both started strategic partnerships in China to work on patient identification technologies. All relevant information has been documented in columns D and E of the attached spreadsheet.

COMPETITIVE LANDSCAPE

MERCK

  • Merck is partnered with Tencent and Alibaba, two companies native to China.
  • Merck is working on an artificial intelligence system with Tencent in China to identify which drugs patients require and are working toward addressing the issues of pharmaceutical e-commerce.
  • Artificial intelligence and other data-based approaches are at the forefront of patient identification.
  • Merck currently is not selling new technology as they are working on developing them with Chinese companies. However, in 2018, Merck was granted a patent application for its proprietary CRISPR technology that is used in genome-editing.

AMGEN

Part
05
of ten
Part
05

Patient ID - Competitive Landscape 3

Novartis and Eli Lilly and Co. have ventured into developing patient identification tools in China through strategic partnerships with Tencent and AmoyDx respectively. Our findings can be found in the attached spreadsheet columns F to H.

FINDINGS

  • Novartis partnered with Tencent to develop platforms to identify, monitor and analyze data from individuals with cardiovascular disease.
  • Novartis partnered with Tencent to help identify patients with cardiovascular disease who need care and also provide the right medicine to the patients.
  • Loxo Oncology, Inc, which is a wholly-owned subsidiary of Eli Lilly and Co, entered into a strategic partnership with AmoyDx and PREMIA Holdings in the ongoing clinical development of LOXO-292 to identify patients with this rare genetic alteration.
  • AmoyDx and PREMIA through the collaboration with Loxo Oncology hope to create the fastest and most efficient patient identification and enrollment network in China and Japan.
  • AmoyDx and PREMIA will provide large-scale cancer patient screening in Asia to support the ongoing clinical development of LOXO-292.

RESEARCH STRATEGY

We couldn't provide information on any patient identification tools by Sanofi in China. We started by searching through the annual reports, press releases, investor relations pages of the company. We expected to find information on what the company is spending on, by checking the annual reports and press releases by Sanofi regarding its activities in China. Unfortunately, we couldn't find any useful information relating to Sanofi's development of patient identification tools in China.

Next, we searched for mentions of Sanofi's activities on media sites such as PRNewswire, Pharmaweek, FiercePharma, Pharmatimes, China Daily, Global Times China, ChinaWhisper, among others. Although we were able to find information on Sanofi's partnerships in China such as the partnership with Ping An Group, there was no further information other than the company is focused on three main areas which are health awareness, quality of care and affordability of care. Using this strategy, we were not able to provide information on the activities of Sanofi concerning patient ID tools.

Then, we searched through patents filed by Sanofi in China to see if the company filed any patent relating to patient ID. We searched sources such as Wipo, Google Patents, Patentscope, FPO, China National Intellectual Property Administration, etc. There was no information on patents filed by the company relating to our research. We also searched through Sanofi's Partnership Brochure, CSR, interviews with the leadership of the company, in an attempt to find any partnerships, what the company is doing and what the leadership of the company is saying regarding their operations in China. This strategy also didn't yield any results.

Part
06
of ten
Part
06

Emerging Tech Companies 2

WeDoctor, a subsidiary of Tencent, wants to improve primary healthcare by providing doctors with AI systems that can help them understand patients' symptoms and suggest diagnoses and treatment plans. Infervision's a Beijing StartUp, uses patient data to build an effective cancer identification tool.

HELPFUL FINDINGS

Chinese AI startup SenseTime developing platforms for healthcare

  • SenseTime, the world's most valuable artificial intelligence (AI) company with a valuation of $4.5 billion is based in China. SenseTime opened a smart health lab in New Jersey, United States. This marked the company's foray into using AI in healthcare for diagnosis and medical treatments.
  • Through the company's SenseCare Smart Health Platform, medical professionals get the support of artificial intelligence to review diagnostic information, plan surgeries, and follow-up management.
  • SenseCare is a smart diagnosis and treatment platform, which can serve the needs of the hospital and process most types of data.
  • SenseCare has the capability of high concurrency of 3D rendering and clinical application. It can show data to patients or users through a visualized interface.
  • This product has been adopted in a hospital in Shanghai, specifically, in the oncology department, to help doctors diagnose cancers.

Tencent is uniquely positioned to leverage patient data for diagnosis

  • Healthcare AI is a priority for Tencent, based on the company’s investments and AI partnerships. More than 38,000 medical institutions have a WeChat account and 60% of those institutions allow patients to book appointments online.
  • Additionally, 2,000 hospitals accept WeChat payment. These services allow Tencent to collect valuable consumer data that helps train AI algorithms.
  • Tencent’s internal R&D efforts resulted in the development of the Miying healthcare AI platform that launched in 2017. This platform helps healthcare professionals diagnose various types of cancers and analyze and manage healthcare records.
  • WeDoctor, a subsidiary of Tencent, wants to improve primary healthcare by providing doctors with AI systems that can help them understand patients' symptoms and suggest diagnoses and treatment plans.
  • At present, WeDoctor has connections with more than 2,700 hospitals in China. The arrangements are made through contracts with local governments, who also have access to the biodata that WeDoctor collects on citizens through its services.

Ping An Good Doctor platform is experiencing rapid growth

  • Ping An Good Doctor is China’s largest online healthcare platform with 54.7 million monthly active users.
  • The company's revenue grew 78.7 per cent in 2018 to 3.33 billion yuan from 2017. Artificial intelligence-assisted family doctor consultation provided 12.3 per cent of revenue, with a gross margin of 40 per cent.
  • The company launched One-minute Clinic, an unmanned AI-powered healthcare clinic. This is part of a growing trend in China to use AI to accelerate healthcare and streamline the number of human medical professionals needed to serve the population.

Infervision's use of patient data to build an effective cancer identification tool.

  • Infervision, a Beijing based startup, has amassed more than a million scans from Chinese hospitals that it’s using to train and test algorithms.
  • Infervision created its algorithm to identify cancerous lung nodules by gathering more than 400,000 lung scans from Chinese partners, such as leading Beijing research centre Peking Union Medical College Hospital and in over two years, it sent each image for review by three radiologists at its Beijing office. Their annotations created the feedstock to train and test image-processing algorithms.
  • In China, Infervision is refining its lung-analysis software to look for other things, like bone fractures and emphysema, and testing algorithms that analyze brain scans for signs of a stroke.

iCarbonX has the intent of digitizing everyone's life information

  • Tencent invested in iCarbonX, a company that aims to develop a digital representation of individuals to help perfect personalized medicine.
  • iCarbonX’s ambition is to build a consumer-facing AI platform that is a one-stop-shop for all things health and wellness from skincare and nutrition recommendations to behavioural health and genetic analysis with users unlocking different functionalities based on their level of membership. At the highest tier, users would even be offered health and life insurance.
  • iCarbonX focus is on providing highly individualized care through massive data sets, biotechnology, and artificial intelligence.
  • iCarbonX promises to mine health data at a speed and scale unmatched by its competitors.
  • As part of the agreement to join iCarbonX’s “digital alliance,” US startups like SomaLogic and HealthTell will commercially launch their genetic tests in China.

Alibaba platform for the healthcare sector

  • In 2017, Alibaba Health launched Doctor You which is an intelligent diagnostics solution that uses image recognition for early diagnosis of cancer.
  • Alibaba Cloud has also partnered with Wuhan Landing Medical High-tech Co. to develop a system that detects early-stage cervical cancer using cell cytology. This system uses advanced visual computation and AI technologies.
  • In March 2017, Alibaba Cloud launched ET Medical Brain, a comprehensive suite of AI-based solutions for the medical industry.
  • Some advanced applications leverage AI-based medical imaging for the diagnosis of diseases and tumours. The solution improves the accuracy of detection and reduces misdiagnosis.

RESEARCH STRATEGY

We could not find companies developing platforms (apps, websites) or technologies which are providing patient identification tools either based in China or serving the Chinese market. The helpful findings detailed above are companies that are building healthcare platforms for diagnostics and personalized medicine by leveraging Big Data and Artificial Intelligence. Patient Identification also requires Artificial Intelligence and Big Data. Therefore, we determined these companies to be the ones most likely to develop patient identification tools and technologies in the future. These companies are Sensetime, Ping An Good Doctor, Infervision, iCarbonX and Alibaba.

To find companies developing patient identification platforms or technologies, we started by searching for healthcare startups in China and companies in the healthcare market by looking through company databases and the China healthcare industry report from sources such as Deloitte, PeW Research, IBIS World etc. On the course of our research, we discovered that 'patient identification' is mostly used within the context of biometric and wearable devices in the healthcare sector. We also tried to determine if international companies (like RightPatient) which provide patient identification tools had ventured into China. Unfortunately, we couldn't any company developing patient ID platforms or tools.

Next, we looked for news articles about patient identification technology in China and this led us to companies like AmoyDx, Congenica and Tencent Holdings, which have already been included in the previous research brief. Using this strategy, we could not find additional companies.

Then, we decided to look for companies building healthcare platforms in China or for the Chinese market, to see if any of them had ventured into patient identification. This is where we found companies like Sensetime, Ping An Good Doctor, Infervision, iCarbonX, Tencent and Alibaba which were leveraging Artificial Intelligence and Big Data for diagnostics and personalized medicine to cater to the Chinese market. But none of the companies is developing tools for patient identification. But because the technology behind diagnostics and personalized medicine could be used to develop the patient identification tools in the future, we decided to include them in the helpful findings.

After exhausting all our research strategies, we concluded that there are no more companies involved in developing platforms or technologies which are providing patient identification tools either based in China or serving the Chinese market.

Part
07
of ten
Part
07

Emerging Tech Companies 3

We have provided a list of 16 companies developing platforms or technologies which are providing patient identification tools in the attached spreadsheet. Companies in this field include; RightPatient, Shenzhen Fidelity Technology Co, Hyan Smartech Co., Ltd, Forecast Health, PatientTouch, Imprivata, UMANICK, ECRI Institute
Identity automation, LifeMed id, Viral Technologies, Zebra, Cleveland Clinic, PDC Healthcare, The Identification Systems Group (ISG) and United Ad Label.

Emerging Tech Companies

  • Shenzhen Fidelity Technology Co developed an FDY-w011 disposable wristband for identifying and managing patients, With soft material, patient's personal information.
  • PatientTouch provides Positive patient identification through barcode verification at the point of care on its platform.
  • UMANICK offers a patient identification technology called UMANICK Identity. UMANICK Identity supports multiple biometric technologies fingerprint, iris, face, and voice recognition.
  • Cleveland clinic has a barcoded patient identification wristband, Nurses can scan the patient identification wristband which opens the patient record in the EMR system.
Part
08
of ten
Part
08

Patient ID Tools - Branded Synthesis

The most relevant data from the individual research reports titled Concept of Patient Identification Tools and Patient ID — Competitive Landscape (parts 1, 2, and 3), as well as Emerging Technology Companies (parts 1, 2, 3, and 4) has been compiled in the attached presentation.

PATIENT IDENTIFICATION TOOLS IN CHINA

OVERVIEW

  • Patient Identification Tools in China serve to link all patient data across multiple systems together to provide a coherent service. Unfortunately, there is a lack of a unique patient identifier that works across multiple hospital information systems such as HIS, LIS, PACS, and others.
  • Electronic health record (EHR) system in China vary significantly by the hospital and are usually not integrated; thus patients often must bring with them a printed health record if they want to see doctors in different hospitals.
  • The current Chinese medical system cannot track a patient through electronic record systems for clinical purposes as there is no unified national platform that can consolidate all the data from all healthcare institutions in China.
  • Vast differences in medical practice raise concerns about the accuracy of data.
  • The lack of an established referral system and the heterogeneity in the quality of healthcare contribute to “medical migration,” when patients travel to different provinces and cities to seek medical care.

SYNTHESIS OF EMERGING TECH COMPANIES

  • The companies developing platforms (apps, websites, and others) or technologies which are providing patient identification tools either based in China or serving the Chinese market are AmoyDx, Congenica, and Tencent Holdings.
  • AmoxyDx is a biotech company. Together with its partner Premia, it is positioning itself "to create the fastest and most efficient patient identification and enrollment network in China."
  • Congenica provides its platform Sapientia and its expertise to allow clinicians to "interrogate the human genome" and distinguish disease-causing variants. It has partnered with Digital China Health Technologies Cooperation Limited (DC Health).
  • Tencent Holdings is creating platforms to identify, monitor, and analyze data from persons with cardiovascular disease. It has partnered with Novartis and Merck & Co.
Part
09
of ten
Part
09

Patient ID - Global (Editable)

  • A compilation of all the components of the Patient Identification Tools project has been provided in an editable Google document for reference.
Part
10
of ten
Part
10

Emerging Tech Companies 4

Ten additional companies that are developing platforms or technologies that provide patient identification tools include HealthCast, iMedOne Mobile from Deutsche Telekom Healthcare, NEC, NextGate, Face Six, BayoMetric, Light Speed Technology, BioEnable, IdentiSys, Indigo from AWARE Biometrics Software and Solutions.
  • All the information has been entered in rows 22 to 31 of the attached spreadsheet.
Sources
Sources

From Part 02
Quotes
  • "A basic requirement to provide patient-centric care is to have identifiers serve to link all patient data across multiple systems together to provide a coherent service. In most hospitals today, the lack of a unique patient identifier that works across multiple hospital information systems such as HIS, LIS, PACS, and others means that healthcare providers typically rely on a patient’s name, date of birth, and other personal information to identify their medical records in the electronic health record systems."
From Part 07
From Part 10
Quotes
  • "RIGHT PATIENT IDENTIFICATION- Accurate patient identification improves patient safety, security, data integrity, and prompt payment while reducing medical record mix-ups, fraud, and human error. "
Quotes
  • "VISUS is a leading provider of process-oriented solutions in image and diagnosis management. From PACS for radiology practices to cross-department and inter-site solutions for hospitals, the JiveX product family covers the entire range of image and diagnostics communication. "
Quotes
  • "One of the toughest challenges healthcare organizations face is identifying potential on-site threats to its facility, patients and staff. NEC's highly accurate facial recognition technologies address these concerns by providing better situational awareness through the use of identification matching software and video surveillance with real-time alerts for greater on-site and patient safety."
Quotes
  • "Our identity management solutions connect the healthcare ecosystem to provide a comprehensive record of care across the enterprise. With our market-leading Enterprise Master Patient Index (EMPI), we help organizations overcome the clinical, operational and financial challenges that result from duplicate records and siloed systems for seamless data exchange, enhanced clinical decision-making and better care."
Quotes
  • "FA6 Med is a face recognition software for hospitals which identifies patients before they get medical treatment, in order to prevent costly medical errors in identification. The FA6 Med starts recognizing patients when they arrive at the reception, and continues throughout the emergency room, hospital departments and in the lab. "
Quotes
  • "Use of Biometrics for Accurate Patient Identification “Throughout the health-care industry, the failure to correctly identify patients continues to result in medication errors, transfusion errors, testing errors, wrong person procedures, and the discharge of infants to the wrong families.” – WHO Report on Patient Identification"
Quotes
  • "BioEnable offer multi biometric patient identification solution, supporting fingerprint, palm vein, iris and face recognition. Our patient identity solution allows hospitals to quickly retrieve a patient’s medical record with a fast Biometric identification. Using biometrics as the patient identifier enables healthcare organizations to prevent duplicate medical records and control fraud while improving patient safety."
Quotes
  • "biometric identity proofing for onboarding of new customers and employees, kiosk-based biometric patient identification"